Skip to content
← All treatment topics

TREATMENT READING

Chronic Myeloid Leukemia

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

44 sections
  1. Treatment Option Overview for CML
  2. Targeted Therapy With Tyrosine Kinase Inhibitors (TKIs)
  3. Allogeneic Bone Marrow Transplant (BMT) or Stem Cell Transplant (SCT)
  4. Interferon Alfa
  5. Hydroxyurea
  6. Treatment of Chronic-Phase CML
  7. Treatment Options for Chronic-Phase CML
  8. Targeted therapy with an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket
  9. Targeted therapy with other BCR::ABL1 TKIs
  10. Can TKIs be discontinued?
  11. Allogeneic BMT or SCT
  12. Treatment of Accelerated-Phase CML
  13. Treatment Options for Accelerated-Phase CML
  14. Targeted therapy with TKIs
  15. Bosutinib
  16. Allogeneic SCT
  17. Treatment of Blastic-Phase CML
  18. Treatment Options for Blastic-Phase CML
  19. Targeted therapy with TKIs
  20. Allogeneic BMT or SCT
  21. Treatment of Relapsed CML
  22. Treatment Options for Relapsed CML
  23. Targeted therapy with TKIs
  24. Ponatinib
  25. Asciminib
  26. Certain factors affect prognosis (chance of recovery) and treatment options.
  27. Chronic myeloid leukemia can relapse (return) after it has been treated.
  28. Treatment Option Overview
  29. Key Points
  30. There are different types of treatment for patients with chronic myeloid leukemia.
  31. The following types of treatment are used:
  32. Targeted therapy
  33. Chemotherapy
  34. Immunotherapy
  35. High-dose chemotherapy with stem cell transplant (SCT)
  36. Donor lymphocyte infusion (DLI)
  37. Surgery
  38. New types of treatment are being tested in clinical trials.
  39. Treatment for chronic myeloid leukemia may cause side effects.
  40. Follow-up care may be needed.
  41. Treatment of Chronic Phase Chronic Myeloid Leukemia
  42. Treatment of Accelerated Phase Chronic Myeloid Leukemia
  43. Treatment of Blastic Phase Chronic Myeloid Leukemia
  44. Treatment of Relapsed Chronic Myeloid Leukemia

Health professional

Treatment Option Overview for CML

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Treatment of patients with chronic myeloid leukemia (CML) is usually initiated at diagnosis, which is based on the presence of an elevated white blood cell count, splenomegaly, thrombocytosis, and identification of the BCR::ABL1 translocation.[1]

Sources: 1

Table 1. Treatment Options for CML Phases
PhaseTreatment Options
BMT = bone marrow transplant; CML = chronic myeloid leukemia; SCT = stem cell transplant; TKIs = tyrosine kinase inhibitors.
Chronic-phase CMLTargeted therapy with an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket
Targeted therapy with other BCR::ABL1 TKIs
Allogeneic BMT or SCT
Accelerated-phase CMLTargeted therapy with TKIs
Allogeneic SCT
Blastic-phase CMLTargeted therapy with TKIs
Allogeneic BMT or SCT
Relapsed CMLTargeted therapy with TKIs

Sources: Targeted therapy with an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket · Targeted therapy with other BCR::ABL1 TKIs · Allogeneic BMT or SCT · Targeted therapy with TKIs · Allogeneic SCT · Targeted therapy with TKIs · Allogeneic BMT or SCT · Targeted therapy with TKIs

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment Option Overview for CML

Targeted Therapy With Tyrosine Kinase Inhibitors (TKIs)

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

The optimal front-line treatment for patients with chronic-phase CML involves specific inhibitors of the BCR::ABL1 tyrosine kinase. Although imatinib mesylate has been extensively studied in patients with CML, TKIs with greater potency and selectivity for BCR::ABL1 than imatinib have also been evaluated.[1-4] Bariatric surgery may impede proper absorption of oral TKIs, resulting in suboptimal responses.[5]

Sources: 1 · 4 · 5

Health professional · Treatment Option Overview for CML

Allogeneic Bone Marrow Transplant (BMT) or Stem Cell Transplant (SCT)

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Allogeneic BMT or SCT has also been used with curative intent.[6] Long-term data beyond 10 years of therapy are available, and most long-term survivors show no evidence of the BCR::ABL1 translocation by any available test (e.g., cytogenetics, reverse transcription–polymerase chain reaction, or fluorescence in situ hybridization). Some patients, however, are not eligible for this approach because of age, comorbid conditions, or lack of a suitable donor. In addition, substantial morbidity and mortality result from allogeneic BMT or SCT; a 5% to 10% treatment-related mortality can be expected, depending on whether a donor is related and the presence of mismatched antigens.[6]

Sources: 6 · 6

Evidence (allogeneic SCT vs. drug treatment):

In a prospective trial of 427 transplant-eligible, previously untreated patients, 166 patients were allocated to allogeneic SCT, and 261 patients were allocated to drug treatment (mostly imatinib).[6][Level of evidence C1] Similar outcomes were seen in patients who underwent allogeneic SCT because of TKI intolerance or nonadherence.[7]

Sources: 6 · Level of evidence C1 · 7

In a prospective trial of 427 transplant-eligible, previously untreated patients, 166 patients were allocated to allogeneic SCT, and 261 patients were allocated to drug treatment (mostly imatinib).[6][Level of evidence C1] Similar outcomes were seen in patients who underwent allogeneic SCT because of TKI intolerance or nonadherence.[7]

No difference in 10-year overall survival was reported between the treatment groups.

Health professional · Treatment Option Overview for CML

Interferon Alfa

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Long-term data are also available for patients treated with interferon alfa.[8-10] Approximately 10% to 20% of these patients have a complete cytogenetic response with no evidence of BCR::ABL1 translocation by any available test, and most of these patients are disease free beyond 10 years. Maintenance therapy with interferon is required, however, and some patients experience side effects that preclude continued treatment.

Sources: 8 · 10

Health professional · Treatment Option Overview for CML

Hydroxyurea

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Hydroxyurea is superior to busulfan in the chronic phase of CML, with significantly longer median survival and significantly fewer severe adverse effects.[11] A dose of 40 mg/kg per day is often used initially, and frequently results in a rapid reduction of the white blood cell (WBC) count. When the WBC count drops below 20 × 109/L, the hydroxyurea dose is often reduced and titrated to maintain a WBC count between 5 × 109/L and 20 × 109/L.

Sources: 11

Hydroxyurea is used primarily to stabilize patients with hyperleukocytosis or as palliative therapy for patients who have not responded to other therapies.

Health professional

Treatment of Chronic-Phase CML

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Health professional · Treatment of Chronic-Phase CML

Treatment Options for Chronic-Phase CML

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Treatment options for chronic-phase chronic myeloid leukemia (CML) include:

Targeted therapy with an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket (asciminib).

Sources: Targeted therapy with an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket

Targeted therapy with other BCR::ABL1 tyrosine kinase inhibitors (TKIs) (nilotinib, dasatinib, bosutinib, or imatinib).

Sources: Targeted therapy with other BCR::ABL1 tyrosine kinase inhibitors (TKIs)

Allogeneic bone marrow transplant (BMT) or stem cell transplant (SCT).

Sources: Allogeneic bone marrow transplant (BMT) or stem cell transplant (SCT)

The preferred initial treatment for patients with newly diagnosed chronic-phase CML could be any of the specific inhibitors of the BCR::ABL1 tyrosine kinase (including asciminib, nilotinib, dasatinib, bosutinib, or imatinib).[1] With any of these agents, the 10-year event-free survival and overall survival (OS) rates exceed 90%.[2-4]

Sources: 1 · 2 · 4

CML response rate abbreviations used in this section include:

DMR: Deep molecular response (previously called CMR [complete molecular response]). This means greater than 4-log reduction (BCR::ABL1 ≤ 0.01%) and is also called MR 4 (molecular response 4). MR 4.5 is designated for BCR::ABL1 ≤ 0.0032%, and MR 5 is designated for BCR::ABL1 ≤ 0.001%.

EMR: Early molecular response. This means a greater than 1-log reduction (BCR::ABL1 ≤ 10%) at 3 months.

MMR: Major molecular response. This means a greater than 3-log reduction (BCR::ABL1 ≤ 0.1%).

A BCR::ABL1 transcript level of 10% or less in patients after 3 months of treatment with a specific TKI (deemed EMR) is associated with the best prognosis in terms of failure-free survival, progression-free survival (PFS), and OS.[5-10] However, in a retrospective analysis, even patients with a BCR::ABL1 transcript level greater than 10% after 3 months of therapy did well when the halving time was less than 76 days.[11]

Sources: 5 · 10 · 11

Mandating a change of therapy based on this 10% transcript level at 3 to 6 months is problematic because 75% of patients do well even with a suboptimal response.[12] After 1 year, the preferred response target is an MMR, which is defined as a BCR::ABL1 level of less than or equal to 0.1%. The optimal target is a DMR, which is defined as under 4 logs (BCR::ABL1 ≤ 0.01%) or undetectable, which is usually a BCR::ABL1 level of less than or equal to 0.001% (MR 5).[13]

Sources: 12 · 13

Health professional · Treatment of Chronic-Phase CML / Treatment Options for Chronic-Phase CML

Targeted therapy with an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Evidence (targeted therapy with an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket):

A prospective study (NCT04971226) included 405 patients with newly diagnosed CML. Patients were randomly assigned to receive asciminib (n = 201) (an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket, a site unique from those used by other TKIs) or either imatinib mesylate (n = 102) or nilotinib, dasatinib, or bosutinib (n = 102).[14]

Sources: NCT04971226 · 14

A prospective study (NCT04971226) included 405 patients with newly diagnosed CML. Patients were randomly assigned to receive asciminib (n = 201) (an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket, a site unique from those used by other TKIs) or either imatinib mesylate (n = 102) or nilotinib, dasatinib, or bosutinib (n = 102).[14]

With a median follow-up of 16.3 months, the 48-week MMR rate was 67.7% for patients who received asciminib and 49% for patients who received imatinib, nilotinib, dasatinib, or bosutinib (P < .002).[14][Level of evidence B3]

Sources: 14 · Level of evidence B3

Patients who received asciminib had fewer grade 3 or greater adverse events (38%) compared with imatinib (44%) and the other TKIs (55%). The rate of discontinuation due to adverse events was lower for patients who received asciminib (5%) compared with patients who received imatinib (11%) or the other TKIs (10%).

Asciminib showed improved efficacy in this early reporting of the trial, and it also showed better tolerability based on adverse events and discontinuations. On this basis, the U.S. Food and Drug Administration approved the use of asciminib as first-line therapy. Use of asciminib will pose significant financial toxicity ($260,000 per year in 2024) versus imatinib ($500 per year in 2024). The price of the other TKIs may decrease because dasatinib is available as a generic, and nilotinib, bosutinib, and ponatinib are expected to be released as generics in 2027.

A prespecified subgroup analysis compared asciminib with the second-generation TKIs (not including imatinib). At week 48, 66.0% of patients who received asciminib had an MMR, and 57.8% of patients who received second-generation TKIs had an MMR. The 8.2% difference was not statistically significant (95% confidence interval [CI], -5.1 to 21.5). In the first year, it appears that the efficacy of asciminib is equivalent to those of second-generation TKIs. Longer follow-up is required to fully assess efficacy and toxicity outcomes.[14]

Sources: 14

Health professional · Treatment of Chronic-Phase CML / Treatment Options for Chronic-Phase CML

Targeted therapy with other BCR::ABL1 TKIs

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Evidence (targeted therapy with other BCR::ABL1 TKIs):

A randomized prospective study of 846 patients compared nilotinib with imatinib.[15][Level of evidence B3]

Sources: 15 · Level of evidence B3

A randomized prospective study of 846 patients compared nilotinib with imatinib.[15][Level of evidence B3]

The rate of MMR at 24 months was 71% and 67% for patients who received two-dose schedules of nilotinib and 44% for patients who received imatinib (P < .0001 for both comparisons).

Progression to accelerated-phase CML or blast crisis occurred in 17 patients who received imatinib (14%), but this progression only occurred in two patients who received nilotinib 300 mg twice daily (<1%, P = .0003) and in five patients who received nilotinib 400 mg twice daily (1.8%, P = .0089).

A randomized prospective study of 519 patients compared dasatinib with imatinib, with the following results:[16][Level of evidence B3]

Sources: 16 · Level of evidence B3

A randomized prospective study of 519 patients compared dasatinib with imatinib, with the following results:[16][Level of evidence B3]

The rate of MMR at 12 months was 46% for patients who received dasatinib and 28% for patients who received imatinib (P < .0001).

The rate of MMR at 24 months was 64% for patients who received dasatinib and 46% for patients who received imatinib (P < .0001).

At 5 years, there was no difference in PFS or OS.

Progression to accelerated-phase CML or blast crisis occurred in 13 patients (5%) who received imatinib and in six patients (2.3%) who received dasatinib (not statistically significant).

In retrospective comparative analyses, a dasatinib dose of 50 mg a day showed equal efficacy to 100 mg, but resulted in fewer pleural effusions (5% vs. 21%).[17][Level of evidence C3]

Sources: 17 · Level of evidence C3

A randomized prospective study of 536 patients compared bosutinib with imatinib.[18][Level of evidence B3]

Sources: 18 · Level of evidence B3

A randomized prospective study of 536 patients compared bosutinib with imatinib.[18][Level of evidence B3]

The MMR rate at 5 years was 73.9% for patients in the bosutinib arm versus 64.6% for patients in the imatinib arm (hazard ratio [HR], 1.57; 95% CI, 1.08–2.28; P = .0075). At 5 years, a DMR (4.5 logs) was attained by 47.4% of patients in the bosutinib arm and 36.6% of patients in the imatinib arm (HR, 1.57; 95% CI, 1.11–2.22).[18]

Sources: 18

Progression to accelerated-phase CML or blast crisis occurred in four patients (1.6%) who received bosutinib and in six patients (2.5%) who received imatinib.

In randomized prospective trials, nilotinib, dasatinib, and bosutinib showed higher rates of earlier MMR compared with imatinib. It is unclear whether this will translate to improved long-term outcomes.[8,9,18][Level of evidence B3] A dose-ranging phase II study of dasatinib in patients older than 70 years showed optimal response and reduction of toxicity starting at 20 mg once daily (with dose escalation if needed), versus the standard dose of 100 mg daily.[19][Level of evidence C3]

Sources: 8 · 9 · 18 · Level of evidence B3 · 19 · Level of evidence C3

Health professional · Treatment of Chronic-Phase CML / Treatment Options for Chronic-Phase CML / Targeted therapy with other BCR::ABL1 TKIs

Can TKIs be discontinued?

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

For patients who obtain a DMR, it is unclear if TKI therapy can be discontinued. Several nonrandomized reports are summarized as follows:[20-24][Level of evidence C3]

Sources: 20 · 24 · Level of evidence C3

Patients who have taken a TKI for more than 3 to 5 years and attained a DMR (molecular remission, 4.5; BCR::ABL1 ≤ 0.0032%) are the best candidates to consider stopping therapy.

50% of patients will experience a relapse of their disease if they discontinue TKI therapy. However, a retrospective analysis with a median follow-up of 3 years found that patients who were in DMR (4 to 4.5 logs) for 5 or more years had a relapse rate of approximately 10%.[25][Level of evidence C3] Another retrospective report with a median of 3 years of follow-up found three measurable factors predictive of MMR maintenance: increased duration of TKI treatment, increased duration of DMR on TKI treatment, and the absence of any peripheral blood blast cells at diagnosis.[20]

Sources: 25 · Level of evidence C3 · 20

Almost all patients who relapse based on BCR::ABL1 quantitative reverse transcription–polymerase chain reaction (RT-PCR) testing can be successfully reinduced with the previous TKI.

However, after the reinduction of a previous TKI, the duration of remissions or the depth of responses are not known. Data to recommend universal discontinuation of TKIs are insufficient, even in patients with a DMR or CMR. Follow-up (i.e., at least every 3 months initially, although the precise interval is not well-defined) is required after stopping therapy because relapses have been noted even after 2 to 3 years. A withdrawal syndrome of muscle and joint pain has been reported after discontinuing TKI therapy.[26] Quality-of-life assessments suggest improved social function, diarrhea, and fatigue after stopping TKI therapy.[27][Level of evidence C1]

Sources: 26 · 27 · Level of evidence C1

Health professional · Treatment of Chronic-Phase CML / Treatment Options for Chronic-Phase CML

Allogeneic BMT or SCT

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Allogeneic BMT or SCT is the only consistently successful curative treatment for patients with CML.[28-30] Patients younger than 60 years with an identical twin or with HLA–matched siblings can consider BMT early in the chronic phase. Although the procedure is associated with considerable acute morbidity and mortality, 50% to 70% of patients who undergo transplant in the chronic phase appear to be cured. The results are better in younger patients, especially for those younger than 20 years. The outcomes of patients who undergo transplant in the accelerated and blastic phases of the disease are progressively worse.[31,32] Most transplant series suggest improved survival when the procedure is performed within 1 year of diagnosis.[33-35][Level of evidence C1] The data supporting early transplant, however, have never been confirmed in controlled trials.

Sources: 28 · 30 · 31 · 32 · 33 · 35 · Level of evidence C1

Evidence (allogeneic SCT):

In a randomized clinical trial, patients underwent allogeneic SCT after receiving preparative therapy with either cyclophosphamide and total-body irradiation (TBI) or busulfan and cyclophosphamide without TBI. The following results were reported:[36][Level of evidence A1]

Sources: 36 · Level of evidence A1

In a randomized clinical trial, patients underwent allogeneic SCT after receiving preparative therapy with either cyclophosphamide and total-body irradiation (TBI) or busulfan and cyclophosphamide without TBI. The following results were reported:[36][Level of evidence A1]

Disease-free survival and OS were comparable between arms.

Busulfan and cyclophosphamide without TBI was associated with less graft-versus-host disease (GVHD) and fewer fevers, hospitalizations, and hospital days.

A retrospective review of 2,444 patients who underwent myeloablative allogeneic SCT reported the following:[37]

Sources: 37

A retrospective review of 2,444 patients who underwent myeloablative allogeneic SCT reported the following:[37]

The 15-year OS rates were 88% (95% CI, 86%–90%) for sibling-matched transplant recipients and 87% (95% CI, 83%–90%) for unrelated-donor transplant recipients.

The cumulative incidences of relapse were 8% (95% CI, 7%–10%) for sibling-matched transplant recipients and 2% (95% CI, 1%– 4%) for unrelated-donor transplant recipients.

In a prospective trial of 354 patients younger than 60 years, 123 of 135 patients with a matched, related donor underwent early allogeneic SCT while the others received interferon-based therapy and imatinib at relapse. Some patients also underwent a matched unrelated-donor SCT in remission.[38][Level of evidence B4]

Sources: 38 · Level of evidence B4

In a prospective trial of 354 patients younger than 60 years, 123 of 135 patients with a matched, related donor underwent early allogeneic SCT while the others received interferon-based therapy and imatinib at relapse. Some patients also underwent a matched unrelated-donor SCT in remission.[38][Level of evidence B4]

With a 9-year median follow-up, survival still favored the drug treatment arm (P = .049), but most of the benefit was early from transplant-related mortality, with the survival curves converging by 8 years.

Although most relapses occur within 5 years of transplant, relapses have occurred as late as 15 years after a BMT.[39] In a molecular analysis of 243 patients who underwent allogeneic BMT over a 20-year interval, only 15% had no detectable BCR::ABL1 transcript by PCR analysis.[40] The risk of relapse appears to be less in patients who underwent transplant early in disease and in patients who developed chronic GVHD.[32,41] In a retrospective review, patients with relapsed disease after allogeneic transplant who received TKI therapy had a 3-year OS rate of 60%.[42][Level of evidence C1]

Sources: 39 · 40 · 32 · 41 · 42 · Level of evidence C1

With the introduction of asciminib, imatinib, dasatinib, bosutinib, and nilotinib therapy, the timing and sequence of allogeneic BMT or SCT has been questioned.[43] Allogeneic SCT is the preferred choice for certain patients presenting with blastic-phase disease, those with a T315I variant and resistance to ponatinib (an oral TKI), and for patients with complete intolerance to the pharmacological options.[44] Similar outcomes were seen in patients who underwent allogeneic SCT because of TKI intolerance or nonadherence.[45]

Sources: 43 · 44 · 45

Health professional

Treatment of Accelerated-Phase CML

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Health professional · Treatment of Accelerated-Phase CML

Treatment Options for Accelerated-Phase CML

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Treatment options for accelerated-phase chronic myeloid leukemia (CML) include:

Targeted therapy with tyrosine kinase inhibitors (TKIs).

Sources: Targeted therapy with tyrosine kinase inhibitors (TKIs)

Targeted therapy with tyrosine kinase inhibitors (TKIs).

Bosutinib.

Sources: Bosutinib

Allogeneic stem cell transplant (SCT).

Sources: Allogeneic stem cell transplant (SCT)

Health professional · Treatment of Accelerated-Phase CML / Treatment Options for Accelerated-Phase CML

Targeted therapy with TKIs

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Health professional · Treatment of Accelerated-Phase CML / Treatment Options for Accelerated-Phase CML / Targeted therapy with TKIs

Bosutinib

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

The U.S. Food and Drug Administration approved bosutinib as a first-line treatment for patients with accelerated-phase CML. These patients were included in the initial phase I/II trial that showed improved efficacy versus imatinib, based on response rates and major molecular response at 5 years of follow-up.[1][Level of evidence C3]

Sources: 1 · Level of evidence C3

Health professional · Treatment of Accelerated-Phase CML / Treatment Options for Accelerated-Phase CML

Allogeneic SCT

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Induction of remission using a TKI and consideration of an allogeneic SCT for patients with poor responses, when feasible, is a standard approach for patients with accelerated-phase CML.[2]

Sources: 2

Evidence (imatinib vs. allogeneic SCT):

A cohort study of 132 patients with accelerated-phase CML compared imatinib with allogeneic SCT as first-line therapy, with a median follow-up of 32 months.[2][Level of evidence C1]

Sources: 2 · Level of evidence C1

A cohort study of 132 patients with accelerated-phase CML compared imatinib with allogeneic SCT as first-line therapy, with a median follow-up of 32 months.[2][Level of evidence C1]

The overall survival rate was improved using allogeneic SCT for the Sokal high-risk patients (100% vs. 17.7%; P = .008).

For Sokal low- and intermediate-risk patients, there were no survival differences between the two first-line approaches.

Health professional

Treatment of Blastic-Phase CML

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Health professional · Treatment of Blastic-Phase CML

Treatment Options for Blastic-Phase CML

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Treatment options for blastic-phase chronic myeloid leukemia (CML) include:

Targeted therapy with tyrosine kinase inhibitors (TKIs).

Sources: Targeted therapy with tyrosine kinase inhibitors (TKIs)

Allogeneic bone marrow transplant (BMT) or stem cell transplant (SCT).

Sources: Allogeneic bone marrow transplant (BMT) or stem cell transplant (SCT)

Health professional · Treatment of Blastic-Phase CML / Treatment Options for Blastic-Phase CML

Targeted therapy with TKIs

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Bosutinib, imatinib mesylate, dasatinib, and nilotinib have demonstrated activity in patients with myeloid blast crisis and lymphoid blast crisis or Philadelphia (Ph) chromosome–positive acute lymphoblastic leukemia (ALL).[1-3]

Sources: 1 · 3

Evidence (targeted therapy with TKIs):

Two trials of imatinib mesylate and one trial of dasatinib involved a total of 518 patients with blastic-phase CML.[2,4,5][Level of evidence C1]

Sources: 2 · 4 · 5 · Level of evidence C1

Two trials of imatinib mesylate and one trial of dasatinib involved a total of 518 patients with blastic-phase CML.[2,4,5][Level of evidence C1]

The studies confirmed a hematologic response rate of 42% to 55% and a major cytogenetic response rate of 16% to 25%, but the estimated 2-year survival rate was below 28%.

Patients with lymphoid blastic-phase CML (as opposed to the more common myeloid blastic phase) have been given the same therapy as patients with Ph chromosome–positive ALL. In a phase II trial, 23 patients with lymphoid blastic-phase CML received hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and dasatinib. The major molecular response rate was 70%, and most patients were referred for allogeneic SCT.[6][Level of evidence C3]

Sources: 6 · Level of evidence C3

A review of 477 patients with blastic-phase CML treated between 1997 and 2016 at a single center showed that 72% had received previous TKI therapy in chronic phase before transformation.[7][Level of evidence C3]

Sources: 7 · Level of evidence C3

A review of 477 patients with blastic-phase CML treated between 1997 and 2016 at a single center showed that 72% had received previous TKI therapy in chronic phase before transformation.[7][Level of evidence C3]

The median overall survival was 12 months.

The median failure-free survival was 5 months.

Patients who could complete an allogeneic SCT fared best, but this may have resulted from selection bias.

Health professional · Treatment of Blastic-Phase CML / Treatment Options for Blastic-Phase CML

Allogeneic BMT or SCT

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Allogeneic BMT or SCT should be considered when feasible, depending on response and durability of response.[8-12]

Sources: 8 · 12

Health professional

Treatment of Relapsed CML

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Health professional · Treatment of Relapsed CML

Treatment Options for Relapsed CML

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Treatment options for relapsed chronic myeloid leukemia (CML) include:

Targeted therapies with tyrosine kinase inhibitors (TKIs).

Sources: Targeted therapies with tyrosine kinase inhibitors (TKIs)

Targeted therapies with tyrosine kinase inhibitors (TKIs).

Ponatinib.

Sources: Ponatinib

Asciminib.

Sources: Asciminib

Relapsed CML is characterized by any evidence of progression of disease from a stable remission. This may include:

Increasing myeloid or blast cells in the peripheral blood or bone marrow.

Cytogenetic positivity when previously cytogenetic negative.

Fluorescence in situ hybridization (FISH) positivity for BCR::ABL1 translocation when previously FISH negative.

Detection of the BCR::ABL1 translocation by reverse transcription–polymerase chain reaction (RT-PCR) during prolonged remissions does not constitute relapse on its own. However, exponential drops in quantitative RT-PCR measurements for 3 to 12 months correlates with the degree of cytogenetic response, just as exponential rises may be associated with quantitative RT-PCR measurements that are closely connected with clinical relapse.[1] Overt treatment failure is defined as a loss of hematologic remission or progression to accelerated-phase or blast crisis phase CML. A consistently rising quantitative RT-PCR BCR::ABL1 level suggests relapsed disease.

Sources: 1 · accelerated-phase · blast crisis phase

Health professional · Treatment of Relapsed CML / Treatment Options for Relapsed CML

Targeted therapy with TKIs

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

In case of treatment failure or suboptimal response, patients should undergo BCR::ABL1 kinase domain mutation analysis to help guide therapy with the newer TKIs or with allogeneic transplant.[2,3]

Sources: 2 · 3

Variants in the tyrosine kinase domain can confer resistance to imatinib mesylate. Alternative TKIs such as dasatinib, nilotinib, or bosutinib, higher doses of imatinib mesylate, and allogeneic stem cell transplant (SCT) have been studied in this setting.[4-16] In particular, the T315I variant marks resistance to imatinib, dasatinib, nilotinib, and bosutinib.

Sources: 4 · 16

Health professional · Treatment of Relapsed CML / Treatment Options for Relapsed CML / Targeted therapy with TKIs

Ponatinib

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Ponatinib is an oral TKI that has activity in patients with T315I variants or in patients for whom another TKI failed.[17-19] Multiple phase II studies concluded that the optimal response (≤1% BCR::ABL1) and least toxicity occurred at a 45 mg starting dose, with a decrease to 15 mg upon achieving the response.[20,21][Level of evidence C3] Ponatinib is associated with increased cardiovascular adverse events. Patients with significant cardiovascular disease, hypertension, or diabetes mellitus have been excluded from clinical trials.[20,21]

Sources: 17 · 19 · 20 · 21 · Level of evidence C3 · 20 · 21

Evidence (ponatinib):

Ponatinib has been studied in multiple phase II studies involving 799 patients.[17,21][Level of evidence C3]

Sources: 17 · 21 · Level of evidence C3

Ponatinib has been studied in multiple phase II studies involving 799 patients.[17,21][Level of evidence C3]

Of the 799 patients with the T315I variant or resistance to two or more prior TKIs, 46% to 68% had an optimal response (≤1% BCR::ABL1) to ponatinib.

In a retrospective review of 184 patients with recurrent chronic CML and the T315I variant, the following was reported:[18][Level of evidence C3]

Sources: 18 · Level of evidence C3

In a retrospective review of 184 patients with recurrent chronic CML and the T315I variant, the following was reported:[18][Level of evidence C3]

Patients treated with ponatinib had a higher 4-year overall survival (OS) rate than did patients treated with allogeneic SCT (73% vs. 56%; hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.16−0.84; P = .017).

For patients with accelerated-phase CML, survival was equivalent; however, for patients with blast crisis-phase CML, OS was worse for those who received ponatinib (HR, 2.29; 95% CI, 1.08−4.82; P = .030).

In a retrospective review, patients with a T315I variant and CML that did not respond to ponatinib had a poor prognosis, with a median survival of 16 months. The outcomes for these patients were best after allogeneic SCT, but this could have resulted from selection bias.[22][Level of evidence C3]

Sources: 22 · Level of evidence C3

A phase II trial of 282 patients was conducted to determine the lowest efficacious dose of ponatinib, because higher doses are correlated with arterial occlusive events.[20]

Sources: 20

A phase II trial of 282 patients was conducted to determine the lowest efficacious dose of ponatinib, because higher doses are correlated with arterial occlusive events.[20]

The optimal dose was found to be an initial 45 mg dose given once daily, then lowered to 15 mg upon achievement of a response (≤1% BCR::ABL1).[20]

Sources: 20

Health professional · Treatment of Relapsed CML / Treatment Options for Relapsed CML / Targeted therapy with TKIs

Asciminib

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 13, 2025. Captured 2026-09-09.

Asciminib is an allosteric inhibitor of BCR::ABL1 at the ABL1 myristoyl pocket, a site unique from those used by TKIs.

Evidence (asciminib):

An open-label randomized clinical trial compared asciminib with bosutinib. With a median follow-up of 14.9 months, 233 patients with refractory or resistant disease were randomly assigned in a 2:1 ratio to receive either asciminib or bosutinib.[23]

Sources: 23

An open-label randomized clinical trial compared asciminib with bosutinib. With a median follow-up of 14.9 months, 233 patients with refractory or resistant disease were randomly assigned in a 2:1 ratio to receive either asciminib or bosutinib.[23]

The major molecular response (MMR) rate at week 24 was 25.5% for patients who received asciminib versus 13.2% for patients who received bosutinib. The difference in response (adjusted for major cytogenetic response at baseline) was 12.2% (95% CI, 2.19%–22.30%; P = .029).[23][Level of evidence B3]

Sources: 23 · Level of evidence B3

Grade 3 or 4 adverse events were experienced by 50.6% of patients who received asciminib and 60.5% of patients who received bosutinib.

A phase I trial of asciminib included heavily pretreated patients who experienced resistance or unacceptable side effects after standard TKIs. Patients with a T315I variant and those in whom ponatinib failed were included.[24][Level of evidence C3]

Sources: 24 · Level of evidence C3

A phase I trial of asciminib included heavily pretreated patients who experienced resistance or unacceptable side effects after standard TKIs. Patients with a T315I variant and those in whom ponatinib failed were included.[24][Level of evidence C3]

Of 141 patients, 48% achieved an MMR by 12 months.

A phase II trial included 31 patients who received asciminib.[25][Level of evidence C3]

Sources: 25 · Level of evidence C3

A phase II trial included 31 patients who received asciminib.[25][Level of evidence C3]

An MMR rate of 41% was reported by 12 months.

Three of nine patients with disease that failed to respond to previous ponatinib responded to asciminib.

For patients · General Information About Chronic Myeloid Leukemia

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

The prognosis and treatment options depend on:

Sources: prognosis

the patient's age

the phase of CML

the amount of blasts in the blood or bone marrow

the patient's general health

For patients · Stages of Chronic Myeloid Leukemia

Chronic myeloid leukemia can relapse (return) after it has been treated.

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

In relapsed CML, the number of blast cells increases after a remission.

Sources: relapsed · CML · blast cells · remission

For patients

Treatment Option Overview

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

There are different types of treatment for patients with chronic myeloid leukemia.

The following types of treatment are used:

The following types of treatment are used:

Targeted therapy

Chemotherapy

Immunotherapy

High-dose chemotherapy with stem cell transplant (SCT)

Donor lymphocyte infusion (DLI)

Surgery

New types of treatment are being tested in clinical trials.

Treatment for chronic myeloid leukemia may cause side effects.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with chronic myeloid leukemia.

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

Different types of treatments are available for chronic myeloid leukemia (CML). You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment. Many factors will be considered, such as the stage of the cancer, your overall health, and your preferences. Your plan will include information about your cancer, the goals of treatment, your treatment options and the possible side effects, and the expected length of treatment.

Talking with your cancer care team before treatment begins about what to expect will be helpful. You'll want to learn what you need to do before treatment begins, how you'll feel while going through it, and what kind of help you will need. To learn more, visit Questions to Ask Your Doctor About Treatment.

Sources: Questions to Ask Your Doctor About Treatment

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.

Sources: Targeted therapy

Tyrosine kinase inhibitor therapy blocks the enzyme tyrosine kinase that causes stem cells to develop into more white blood cells (blasts) than the body needs.Tyrosine kinase inhibitors used to treat CML include:Having bariatric surgery may block some absorption of oral tyrosine kinase inhibitors, limiting their effectiveness.

Sources: Tyrosine kinase inhibitor therapy · enzyme · stem cells · white blood cells · blasts · bariatric surgery · oral

Tyrosine kinase inhibitor therapy blocks the enzyme tyrosine kinase that causes stem cells to develop into more white blood cells (blasts) than the body needs.Tyrosine kinase inhibitors used to treat CML include:Having bariatric surgery may block some absorption of oral tyrosine kinase inhibitors, limiting their effectiveness.

asciminib

Sources: asciminib

imatinib mesylate

dasatinib

nilotinib

Sources: nilotinib

bosutinib

Sources: bosutinib

Learn more about Targeted Therapy to Treat Cancer and Drugs Approved for Chronic Myeloid Leukemia.

Sources: Targeted Therapy to Treat Cancer · Drugs Approved for Chronic Myeloid Leukemia

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: Chemotherapy · injected · systemic chemotherapy

Learn more about Chemotherapy to Treat Cancer and Drugs Approved for Chronic Myeloid Leukemia.

Sources: Chemotherapy to Treat Cancer · Drugs Approved for Chronic Myeloid Leukemia

For patients · Treatment Option Overview / The following types of treatment are used:

Immunotherapy

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer. Interferon is a type of immunotherapy used to treat CML. It affects the division of cancer cells and can slow tumor growth.

Sources: Immunotherapy · immune system · Interferon

Learn more about Immunotherapy to Treat Cancer and Drugs Approved for Chronic Myeloid Leukemia.

Sources: Immunotherapy to Treat Cancer · Drugs Approved for Chronic Myeloid Leukemia

For patients · Treatment Option Overview / The following types of treatment are used:

High-dose chemotherapy with stem cell transplant (SCT)

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

High doses of chemotherapy are given to kill cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.

Sources: blood · Stem cells · bone marrow · donor · infusion

Learn more about Stem Cell Transplants in Cancer Treatment.

Sources: Stem Cell Transplants in Cancer Treatment

For patients · Treatment Option Overview / The following types of treatment are used:

Donor lymphocyte infusion (DLI)

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

Donor lymphocyte infusion (DLI) is a cancer treatment that may be used after stem cell transplant. Lymphocytes (a type of white blood cell) from the stem cell transplant donor are removed from the donor's blood and may be frozen for storage. The donor's lymphocytes are thawed if they were frozen and then given to the patient through one or more infusions. The lymphocytes see the patient's cancer cells as not belonging to the body and attack them.

Sources: Donor lymphocyte infusion · Lymphocytes · white blood cell

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

Splenectomy is surgery to remove the spleen.

Sources: spleen

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Treatment Option Overview

Treatment for chronic myeloid leukemia may cause side effects.

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Chronic Phase Chronic Myeloid Leukemia

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

Treatment of chronic phase chronic myeloid leukemia may include:

targeted therapy (asciminib, imatinib mesylate, nilotinib, dasatinib, bosutinib)

Sources: targeted therapy · asciminib · imatinib mesylate · nilotinib · dasatinib · bosutinib

allogeneic bone marrow transplant or stem cell transplant

Sources: allogeneic bone marrow transplant · stem cell transplant

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Accelerated Phase Chronic Myeloid Leukemia

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

Treatment of accelerated phase chronic myeloid leukemia may include:

targeted therapy (bosutinib)

targeted therapy (imatinib mesylate) followed by allogeneic stem cell transplant

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Blastic Phase Chronic Myeloid Leukemia

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

Treatment of blastic phase chronic myeloid leukemia may include:

targeted therapy (imatinib mesylate, dasatinib, nilotinib, bosutinib)

allogeneic bone marrow transplant or stem cell transplant

chemotherapy as palliative therapy to relieve symptoms and improve quality of life

Sources: chemotherapy · palliative therapy · symptoms · quality of life

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Relapsed Chronic Myeloid Leukemia

Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 9, 2025. Captured 2026-09-09.

In relapsed chronic myeloid leukemia (CML), the number of blast cells increases after a remission. Treatment of relapsed CML may include targeted therapy (ponatinib or asciminib).

Sources: relapsed · blast cells · remission · ponatinib

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

NCT00109707 · COMPLETED · phase1, phase2

Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis

ClinicalTrials.gov record

Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

NCT00123474 · COMPLETED · phase3

Myeloid Leukemia, Chronic, Chronic-Phase

ClinicalTrials.gov record

Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML

NCT00123487 · COMPLETED · phase3

Myeloid Leukemia, Chronic, Accelerated Phase, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

ClinicalTrials.gov record

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

NCT00261846 · COMPLETED · phase2

Chronic Myeloid Leukemia

ClinicalTrials.gov record

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

NCT00471497 · COMPLETED · phase3

Myelogenous Leukemia, Chronic

ClinicalTrials.gov record

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

NCT00481247 · COMPLETED · phase3

Myeloid Leukemia, Chronic

ClinicalTrials.gov record

Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

NCT01207440 · COMPLETED · phase2

Chronic Myeloid Leukemia, Ph+ Acute Lymphoblastic Leukemia

ClinicalTrials.gov record

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

NCT01698905 · COMPLETED · phase2

Chronic Myeloid Leukemia

ClinicalTrials.gov record

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

NCT01784068 · COMPLETED · phase2

Chronic Myelogenous Leukemia

ClinicalTrials.gov record

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

NCT02081378 · COMPLETED · phase1

Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

ClinicalTrials.gov record

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NCT02130557 · COMPLETED · phase3

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

ClinicalTrials.gov record

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

NCT02467270 · COMPLETED · phase2

Myeloid Leukemia, Chronic, Chronic Phase

ClinicalTrials.gov record

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

NCT03106779 · COMPLETED · phase3

Chronic Myelogenous Leukemia

ClinicalTrials.gov record

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

NCT04971226 · ACTIVE NOT RECRUITING · phase3

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

ClinicalTrials.gov record

Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate

NCT00038675 · COMPLETED · na

Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera, Hypereosinophilic Syndrome, Mastocytosis

ClinicalTrials.gov record

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

NCT00381550 · COMPLETED · phase2

Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia,...

ClinicalTrials.gov record

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

NCT00397813 · COMPLETED · phase2

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myeloproliferative Neoplasm,...

ClinicalTrials.gov record

Aflibercept in Treating Patients With Myelodysplastic Syndromes

NCT00509249 · TERMINATED · phase2

Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm,...

ClinicalTrials.gov record

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

NCT00579111 · TERMINATED · phase1, phase2

Myelodysplastic and Myeloproliferative Disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Plasma Cell...

ClinicalTrials.gov record

Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation

NCT00626626 · TERMINATED · phase1, phase2

Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma

ClinicalTrials.gov record

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

NCT01338987 · COMPLETED · phase2

Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia

ClinicalTrials.gov record

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

NCT01350258 · TERMINATED · phase1, phase2

Hematologic Malignancies, Acute Leukemia, Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myeloma, Chronic...

ClinicalTrials.gov record

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

NCT02145039 · TERMINATED · na

Acute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia

ClinicalTrials.gov record

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

NCT02639559 · COMPLETED · phase2

Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease, Hodgkins Disease,...

ClinicalTrials.gov record

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

NCT02988466 · COMPLETED · phase2

Hematologic Malignancies

ClinicalTrials.gov record

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

NCT03018223 · COMPLETED · phase1

Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Hodgkin...

ClinicalTrials.gov record

Disease and treatment settings

Chronic Myeloid Leukemia

Disease and treatment setting

Chronic Myeloid Leukemia

Gleevec: chronic myeloid leukemia after prior therapy

Disease and treatment setting

Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.

IMKELDI: chronic myeloid leukemia after prior therapy

Disease and treatment setting

Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.

recurrent Chronic Myeloid Leukemia

Disease and treatment setting

Treatment of Relapsed CML

Drug labels

BOSULIF

Label date 2026-05-28

BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or...

DailyMed label

BOSULIF

Label date 2026-03-10

BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or...

DailyMed label

CAVHANZA

Label date 2026-08-07

CAVHANZA is a kinase inhibitor indicated for the treatment of: Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase (CP) and...

DailyMed label

DANZITEN

Label date 2025-07-28

DANZITEN is a kinase inhibitor indicated for the treatment of: • Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) • Adult patients with chronic phase (CP)...

DailyMed label

Dasatinib

Label date 2024-07-09

Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid blast phase...

DailyMed label

Gleevec

Label date 2026-07-13

Gleevec is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia...

DailyMed label

HYDREA

Label date 2026-01-26

HYDREA is indicated for the treatment of: • Resistant chronic myeloid leukemia. • Locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. HYDREA is an antimetabolite...

DailyMed label

HYDREA

Label date 2025-09-15

HYDREA is indicated for the treatment of: Resistant chronic myeloid leukemia. Locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. HYDREA is an antimetabolite indicated...

DailyMed label

Iclusig

Label date 2026-08-14

ICLUSIG ® is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy. This indication is approved under...

DailyMed label

IMKELDI

Label date 2024-12-05

Imkeldi is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia...

DailyMed label

MYLERAN

Label date 2025-01-08

INDICATIONS AND USAGE MYLERAN (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia.

DailyMed label

Nilotinib

Label date 2025-07-02

Nilotinib Capsules is a kinase inhibitor indicated for the treatment of: Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase...

DailyMed label

Nilotinib

Label date 2025-11-14

Nilotinib Capsules is a kinase inhibitor indicated for the treatment of: Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Adult patients with chronic phase...

DailyMed label

PHYRAGO

Label date 2025-08-23

1. INDICATIONS AND USAGE PHYRAGO is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lymphoid...

DailyMed label

SCEMBLIX

Label date 2025-11-25

SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on...

DailyMed label

SPRYCEL

Label date 2026-08-21

SPRYCEL (dasatinib) is indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • chronic, accelerated, or myeloid or lymphoid blast...

DailyMed label

TABLOID

Label date 2025-01-08

INDICATIONS AND USAGE a) Acute Nonlymphocytic Leukemias TABLOID brand Thioguanine is indicated for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. However, it is not recommended for use...

DailyMed label

Tasigna

Label date 2025-12-16

Tasigna is a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase....

DailyMed label